• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Emory University - Articles and news items

phantom limb

Pioneering treatment could freeze out phantom limb pain

Industry news / 6 April 2016 / Victoria White

Cryoablation therapy, a targeted treatment using cold blasts, shows promise in improving the quality of life for patients suffering phantom limb pain…

Shi-Yong Sun

Can mTOR kinase inhibitors beat rapalogues in fighting against cancer?

Cancer Biology, Issue 1 2014 / 19 February 2014 / Shi-Yong Sun, Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute

The mammalian target of rapamycin (mTOR) has emerged as a promising cancer therapeutic target. Some rapamycin analogues (rapalogues) as mTOR allosteric inhibitors are FDA-approved drugs for treatment of certain types of cancers. However, the modest clinical anticancer activity of rapalogues, which preferentially inhibit mTOR complex 1, in most types of cancer, has spurred the development of ATP competitive mTOR kinase inhibitors (TORKinibs) that inhibit both mTOR complex 1 and complex 2, in the hope of developing a novel generation of mTOR inhibitors with better therapeutic efficacy than rapalogues. So far, several TORKinibs have been developed and some are under clinical testing. With a strong rationale, we expect great success in the treatment of cancer with TORKinibs.

Bristol Myers Squibb logo

Bristol-Myers Squibb and Emory University announce partnership

Industry news, News / 21 June 2012 / Bristol-Myers Squibb Company

First studies under the agreement to focus on clinical trial programs in oncology…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +